Although the sample sizes are small in this study and immunohistochemistry was performed using commercially available non-validated reagents, our results highlight the importance of the DSC3 marker in understanding the nature of immunological differences in bladder cancer subtypes and cancer prognosis. This evidence concerns the gene DSC3 and cancer.